JP2024537394A - 修飾タンパク質およびタンパク質分解剤 - Google Patents
修飾タンパク質およびタンパク質分解剤 Download PDFInfo
- Publication number
- JP2024537394A JP2024537394A JP2024522487A JP2024522487A JP2024537394A JP 2024537394 A JP2024537394 A JP 2024537394A JP 2024522487 A JP2024522487 A JP 2024522487A JP 2024522487 A JP2024522487 A JP 2024522487A JP 2024537394 A JP2024537394 A JP 2024537394A
- Authority
- JP
- Japan
- Prior art keywords
- pharma
- acceptable salt
- optionally substituted
- ceutically acceptable
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021123848 | 2021-10-14 | ||
| CNPCT/CN2021/123848 | 2021-10-14 | ||
| CNPCT/CN2021/133363 | 2021-11-26 | ||
| CN2021133363 | 2021-11-26 | ||
| PCT/CN2022/125080 WO2023061440A1 (en) | 2021-10-14 | 2022-10-13 | Modified proteins and protein degraders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024537394A true JP2024537394A (ja) | 2024-10-10 |
| JP2024537394A5 JP2024537394A5 (cg-RX-API-DMAC7.html) | 2025-10-21 |
Family
ID=85987275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024522487A Pending JP2024537394A (ja) | 2021-10-14 | 2022-10-13 | 修飾タンパク質およびタンパク質分解剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250235543A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4416145A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024537394A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118451078A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022362494A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3234615A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL312013A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024004525A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023061440A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3217792A1 (en) | 2021-05-07 | 2022-11-10 | Kymera Therapeutics, Inc | Cdk2 degraders and uses thereof |
| WO2024072794A1 (en) * | 2022-09-26 | 2024-04-04 | Rectify Pharmaceuticals, Inc. | Pyridine carboxamide compounds and their use in treating medical conditions |
| CN121005703A (zh) * | 2024-05-24 | 2025-11-25 | 中国科学院广州生物医药与健康研究院 | 一种酰胺吲嗪类化合物及其制备方法和应用 |
| WO2026107421A1 (en) * | 2024-11-18 | 2026-05-21 | Bristol-Myers Squibb Company | 1 h-benzo[d]imidazole derivatives as camk2 inhibitors for the treatment of heart failure |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018119357A1 (en) * | 2016-12-24 | 2018-06-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| JP2019514883A (ja) * | 2016-04-22 | 2019-06-06 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | サイクリン依存性キナーゼ4/6(cdk4/6)阻害剤のe3リガーゼリガンドとのコンジュゲーションによるcdk4/6の分解および使用法 |
| JP2020514252A (ja) * | 2016-12-08 | 2020-05-21 | アイカーン スクール オブ メディスン アット マウント シナイ | Cdk4/6媒介性がんを治療するための組成物および方法 |
| WO2020207396A1 (en) * | 2019-04-09 | 2020-10-15 | Ranok Therapeutics (Hangzhou) Co. Ltd. | Methods and compositions for targeted protein degradation |
| WO2021061151A1 (en) * | 2019-09-27 | 2021-04-01 | Romark Laboratories L.C. | Screening for anti-hepatitis b compounds |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201522337A (zh) * | 2013-03-12 | 2015-06-16 | Arqule Inc | 經取代之三環吡唑並-嘧啶化合物類 |
| CA3103185A1 (en) * | 2018-06-13 | 2019-12-19 | Amphista Therapeutics Ltd | Bifunctional molecules for targeting rpn11 |
| WO2020092662A1 (en) * | 2018-11-02 | 2020-05-07 | The Wistar Institute Of Anatomy And Biology | Proteolysis-targeting chimeras |
| EA202192260A1 (ru) * | 2019-02-15 | 2021-12-17 | Инсайт Корпорейшн | Биомаркеры циклин-зависимой киназы 2 и их применение |
| CN113646002A (zh) * | 2019-02-27 | 2021-11-12 | 上海睿跃生物科技有限公司 | 环amp反应元件结合蛋白(cbp)和/或300kda腺病毒e1a结合蛋白(p300)降解化合物和使用方法 |
| JP2022529700A (ja) * | 2019-04-23 | 2022-06-23 | ダナ-ファーバー キャンサー インスティテュート,インコーポレイテッド | サイクリン依存性キナーゼ12(cdk12)の分解剤およびその使用 |
| CN112409376A (zh) * | 2019-08-20 | 2021-02-26 | 华东师范大学 | 一种基于dcaf15的蛋白降解靶向嵌合体及其制备方法和应用 |
| CN114502534A (zh) * | 2019-09-30 | 2022-05-13 | 协和麒麟株式会社 | Bet降解剂 |
| WO2021239117A1 (en) * | 2020-05-28 | 2021-12-02 | Cullgen (Shanghai) , Inc. | Modified proteins and protein degraders |
| CN116507333B (zh) * | 2020-08-27 | 2025-05-09 | 上海睿跃生物科技有限公司 | 环amp反应元件结合蛋白(cbp)和/或300kda腺病毒e1a结合蛋白(p300)降解化合物和使用方法 |
| TW202423914A (zh) * | 2022-08-19 | 2024-06-16 | 美商凱麥拉醫療公司 | Cdk2降解劑及其用途 |
| US20240174665A1 (en) * | 2022-08-19 | 2024-05-30 | Kymera Therapeutics, Inc. | Cdk2 inhibitors and uses thereof |
-
2022
- 2022-10-13 AU AU2022362494A patent/AU2022362494A1/en active Pending
- 2022-10-13 CN CN202280082680.9A patent/CN118451078A/zh active Pending
- 2022-10-13 US US18/700,898 patent/US20250235543A1/en active Pending
- 2022-10-13 EP EP22880376.3A patent/EP4416145A4/en active Pending
- 2022-10-13 IL IL312013A patent/IL312013A/en unknown
- 2022-10-13 MX MX2024004525A patent/MX2024004525A/es unknown
- 2022-10-13 CA CA3234615A patent/CA3234615A1/en active Pending
- 2022-10-13 WO PCT/CN2022/125080 patent/WO2023061440A1/en not_active Ceased
- 2022-10-13 JP JP2024522487A patent/JP2024537394A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019514883A (ja) * | 2016-04-22 | 2019-06-06 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | サイクリン依存性キナーゼ4/6(cdk4/6)阻害剤のe3リガーゼリガンドとのコンジュゲーションによるcdk4/6の分解および使用法 |
| JP2020514252A (ja) * | 2016-12-08 | 2020-05-21 | アイカーン スクール オブ メディスン アット マウント シナイ | Cdk4/6媒介性がんを治療するための組成物および方法 |
| WO2018119357A1 (en) * | 2016-12-24 | 2018-06-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| WO2020207396A1 (en) * | 2019-04-09 | 2020-10-15 | Ranok Therapeutics (Hangzhou) Co. Ltd. | Methods and compositions for targeted protein degradation |
| WO2021061151A1 (en) * | 2019-09-27 | 2021-04-01 | Romark Laboratories L.C. | Screening for anti-hepatitis b compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| CN118451078A (zh) | 2024-08-06 |
| AU2022362494A1 (en) | 2024-05-23 |
| EP4416145A4 (en) | 2026-05-27 |
| CA3234615A1 (en) | 2023-04-20 |
| MX2024004525A (es) | 2024-05-24 |
| WO2023061440A1 (en) | 2023-04-20 |
| IL312013A (en) | 2024-06-01 |
| EP4416145A1 (en) | 2024-08-21 |
| US20250235543A1 (en) | 2025-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11884680B2 (en) | Bromodomain inhibitors | |
| US20250235543A1 (en) | Modified proteins and protein degraders | |
| TWI770527B (zh) | Cot 調節劑及其使用方法 | |
| CN109071552B (zh) | 细胞周期蛋白依赖性激酶4/6(cdk4/6)通过cdk4/6抑制剂与e3连接酶配体的缀合的降解及使用方法 | |
| AU2013305634B2 (en) | Novel 4,6-disubstituted aminopyrimidine derivatives | |
| BG106678A (bg) | ПИРАЗОЛО [4,3 - d] ПИРИМИДИНОВИ ПРОИЗВОДНИ | |
| AU2023271807A1 (en) | Inhibitors of parg | |
| WO2009085256A1 (en) | Anti-hiv compounds | |
| JP2017515848A (ja) | タンパク質脱アセチル化酵素阻害剤およびタンパク質脱アセチル化酵素−タンパク質キナーゼ二重阻害剤としての複素環式ヒドロキサム酸ならびにその使用方法 | |
| JP6797923B2 (ja) | Alkおよびsrpk阻害剤ならびに使用方法 | |
| CN108463222A (zh) | 用于治疗疾病的杂环化合物 | |
| JP4721452B2 (ja) | Pde7阻害作用を有するピリジニルピラゾロピリミジノン誘導体 | |
| JP2008501618A6 (ja) | Pde7阻害作用を有するピリジニルピラゾロピリミジノン誘導体 | |
| JP2025500871A (ja) | ピリミジン又はピリジン誘導体及びその医薬用途 | |
| CN107743489A (zh) | 用于治疗免疫疾病、炎性疾病或者癌症的7‑(吗啉‑4‑基)吡唑并[1,5‑a]嘧啶衍生物 | |
| CN115996911A (zh) | 具有p2x4受体拮抗活性的取代的n-苯乙酰胺 | |
| JP2024516194A (ja) | Pd1/pd-l1阻害剤としての化合物及びその方法 | |
| WO2004101567A1 (en) | 2-SUBSTITUTED PHENYL -6,8-DIALKYL-3H-IMIDAZOLE [1,5a][1,3,5] TRIAZINE -4- ONE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF | |
| HK1229722B (en) | Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240516 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251010 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251010 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20260717 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260805 |